Max Hodak's Science Corp. Prepares First Human Brain Sensor Implant

Max Hodak's Science Corp. is preparing its first human brain sensor implant, a significant step forward in brain-computer interfaces.

Max Hodak's Science Corp. Prepares First Human Brain Sensor Implant
Science Corp. logo with an illustration of a brain sensor

Science Corp., founded by Max Hodak, former president of Neuralink, is preparing its first human brain sensor implant. The device aims to establish a direct connection between the human brain and electronics, using a biohybrid approach that combines neurons grown in the laboratory with electronic components. The goal is to create more natural and integrated brain-computer interfaces that overcome the limitations of traditional electronic implants.

The Role of Dr. Murat Günel

To lead this initiative, Science Corp. has recruited Dr. Murat Günel, chair of the Department of Neurosurgery at the Yale School of Medicine, as its scientific advisor. After two years of discussions, Dr. Günel agreed to work with the company on implementing the sensor in the human brain. His role will be crucial in ensuring the safety and effectiveness of the implant during the early stages of clinical trials.

Biohybrid Approach and Device Development

The device developed by Science Corp. is designed to be implanted on top of the cerebral cortex, reducing the risk of damage to surrounding brain tissue. This approach aims to minimize the complications associated with traditional implants, which often require insertion directly into the brain. The sensor has 520 recording electrodes, packed into an area the size of a pea, and contains a silicon honeycomb structure with 100,000 "microspheres" where living neurons grow directly into brain tissue. This innovative design facilitates the integration of cultured neurons with the patient's own, creating a biological connection between electronics and the brain.

Future Prospects and Therapeutic Applications

If clinical trials are successful, the sensor could open new avenues in treating a range of neurological conditions. Potential applications include gentle electrical stimulation to promote the healing of damaged brain or spinal cord cells, monitoring neurological activity in patients with brain tumors, and providing early warnings of possible seizures. In addition, the biohybrid approach could offer more effective treatments for neurodegenerative diseases such as Parkinson's, combining electronics with biological systems to halt or slow disease progression.

Next Steps and Timeline

Science Corp. is currently preparing device prototypes and working on growing neuronal cells for various therapeutic applications, ensuring they meet the standards for medical use. Dr. Günel is working with medical ethics committees to plan the clinical trials, with the goal of starting the first phases of human testing in 2027. These initial trials will focus on assessing the safety and effectiveness of the sensor implanted on top of the cerebral cortex, without the immediate inclusion of cultured neurons. The company then plans to integrate biohybrid neurons to further evaluate the device's therapeutic potential.

Takeaways

  • Innovation in brain implant design: Science Corp.'s biohybrid approach represents a significant advance over traditional electronic implants, aiming for greater integration and biocompatibility.
  • Collaboration with leading experts: The inclusion of Dr. Murat Günel as scientific advisor underscores the company's commitment to responsible research and development of advanced medical technologies.
  • Potential therapeutic impact: If clinical trials succeed, the sensor could transform the treatment of a range of neurological conditions, offering new hope to patients.
  • Clinical trial timeline: With the goal of starting human trials in 2027, Science Corp. is working to ensure the device meets medical standards and applicable regulations.
  • Future outlook: The success of this project could pave the way for further innovation in brain-computer interfaces, with applications ranging from medicine to human augmentation.

For further details, see the original article on TechCrunch.